Iluvien Phase III Data Positive Based on Combined Studies Nov. 1, 2011 By Catherine Hollingsworth No Comments No AbstractRead More
Past Funding Woes, Thallion Gets Cash, E. Coli Drug Partner Nov. 1, 2011 By Catherine Hollingsworth No Comments No AbstractRead More
Pharmaxis Hits the Mark in Phase III Cystic Fibrosis Trial Nov. 1, 2011 By Catherine Hollingsworth No Comments No AbstractRead More
Titan's Trial in Parkinson's Disease Misses Endpoints Nov. 1, 2011 By Catherine Hollingsworth No Comments No AbstractRead More
Genzyme Plan Will Tie Pay to Broader Performance Oct. 31, 2011 By Catherine Hollingsworth No Comments No AbstractRead More
NewCo News: Centrose Seeks Funds for Low-Tox EDC Phase I Trials Oct. 15, 2010 By Catherine Hollingsworth No Comments
Morphosys Pairs Antibody Platform with Sloning's Oct. 13, 2010 By Catherine Hollingsworth No Comments
Exelixis, BMS Ink More Deals Worth Total Potential $565M Oct. 12, 2010 By Catherine Hollingsworth No Comments Exelixis Inc. continued its cozy relationship with longtime partner Bristol-Myers Squibb Co., entering two more agreements worth a combined potential $565 million. (BioWorld Today)Read More
Cytori to Fatten its Coffers With $16.8M Stock Sale Oct. 11, 2010 By Catherine Hollingsworth No Comments
